Claudia Valverde
Overview
Explore the profile of Claudia Valverde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Puerto D, Cicala C, Valverde C, Serrano C
Expert Opin Emerg Drugs
. 2025 Jan;
:1-18.
PMID: 39874592
Introduction: Sarcomas are a rare and diverse group of mesenchymal-origin solid tumors, constituting only 1% of adult malignancies and classified into soft tissue and bone sarcomas. For localized diseases, surgery...
2.
Cicala C, Matito J, Quindos M, Gomez-Peregrina D, Romero-Lozano P, Fernandez-Suarez P, et al.
JCO Precis Oncol
. 2025 Jan;
9():e2400497.
PMID: 39787462
Purpose: Less than 5% of GI stromal tumors (GISTs) are driven by the loss of the succinate dehydrogenase (SDH) complex, resulting in a pervasive DNA hypermethylation pattern that leads to...
3.
Ortega-Bertran S, Fernandez-Rodriguez J, Magallon-Lorenz M, Zhang X, Creus-Bachiller E, Diazgranados A, et al.
Clin Cancer Res
. 2025 Jan;
31(5):907-920.
PMID: 39786423
Purpose: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft-tissue sarcoma that develops sporadically or in patients with neurofibromatosis type 1 (NF1). Its development is marked by the inactivation...
4.
Salazar J, Arranz M, Martin-Broto J, Bautista F, Martinez-Garcia J, Martinez-Trufero J, et al.
Pharmaceutics
. 2025 Jan;
16(12.
PMID: 39771563
Osteosarcoma is a rare disease, but it is the most frequent malignant bone tumor. Primary treatment consists of preoperative MAP (methotrexate (MTX), doxorubicin and cisplatin) chemotherapy followed by surgery and...
5.
Livingston J, Blay J, Trent J, Valverde C, Agulnik M, Gounder M, et al.
Clin Cancer Res
. 2024 Dec;
31(4):628-638.
PMID: 39660994
Purpose: FHD-609, a potent, selective, heterobifunctional degrader of bromodomain-containing protein 9 (BRD9), was evaluated for treating patients with advanced synovial sarcoma or SMARCB1-deficient tumors. Patients And Methods: In this multinational,...
6.
Palmerini E, Lopez Pousa A, Grignani G, Redondo A, Hindi N, Provenzano S, et al.
Cancer
. 2024 Nov;
131(1):e35628.
PMID: 39540661
Background: Herein, we present the results of the phase 2 IMMUNOSARC study (NCT03277924), investigating sunitinib and nivolumab in adult patients with advanced bone sarcomas (BS). Methods: Progressing patients with a...
7.
Mondaza-Hernandez J, Hindi N, Fernandez-Serra A, Ramos R, Gonzalez-Campora R, Gomez-Mateo M, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241293951.
PMID: 39502403
Background: Alveolar soft-part sarcoma (ASPS) is a rare tumor driven by the ASPSCR1-TFE3 fusion protein, with a propensity for metastasis. Prognostic factors remain poorly understood, and traditional chemotherapies are largely...
8.
Martin-Broto J, Diaz-Beveridge R, Moura D, Ramos R, Martinez-Trufero J, Carrasco I, et al.
J Clin Oncol
. 2024 Oct;
43(3):297-307.
PMID: 39356980
Purpose: Doxorubicin, alongside a select group of cytotoxic agents, is capable of inducing an adaptive immune response via a well-established peculiar type of tumor cell death called immunogenic cell death...
9.
Moura D, Lopez-Marti J, Benesova I, de Andrea C, di Lernia D, Lacerenza S, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5192-5206.
PMID: 39283727
Purpose: The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled...
10.
Carrillo-Garcia J, Hindi N, Conceicao M, Sala M, Ugalde A, Lopez-Pousa A, et al.
Eur J Cancer
. 2024 Aug;
209:114270.
PMID: 39142211
Purpose: Prognostic biomarkers remain necessary in sporadic desmoid tumor (DT) because the clinical course is unpredictable. DT location along with gene expression between thoracic and abdominal wall locations was analyzed....